← AIM ImmunoTech Inc. (AIM) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
AIM ImmunoTech Inc. (AIM)
Biological Products, (No Diagnostic Substances) · market cap $6M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-16 (est.)
Earnings
Pipeline
5
programs
Upcoming events
1
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-11-16 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Alferon LDO | Phase 2 | Severe Acute Respiratory Syndrome |
| Rintatolimod | Phase 2 | Post COVID-19 Condition |
| Ampligen | Phase 3 | Chronic Fatigue Syndrome |
| poly I-poly C12U | Phase 2 | HIV Seropositivity |
| AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide | Phase 2 | Asthma |
Price & technical context
3-month
-33.3%
6-month
-65.4%
12-month
-92.8%
52-wk range
$0.17–$2.68
vs 50-day MA
-20.5%
vs 200-day MA
-68.3%
Realized vol
174.9%
Max drawdown
-99.4%
Daily closes through 2026-10-09. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AIM (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.